Spindle cell angiosarcoma following irradiation therapy for cervical carcinoma.
BACKGROUND
Angiosarcomas arise in the scalp and face in the elderly, in association with chronic lymphedema (Stewart-Treves syndrome), and in irradiated areas. Rarely in these settings, angiosarcomas exhibit pure spindle cell phenotype.


METHODS
Herein, the clinicopathologic features of a 72-year-old-woman with spindle cell angiosarcoma are described.


RESULTS
A 72-year-old woman presented with numerous nodules and diffuse induration from the lower abdomen to the right buttock, corresponding to the area exposed to 60Co-irradiation during treatment for cervical carcinoma 10 years earlier. Histopathological examination revealed inflitrative, atypical, spindle cells that labeled with antibodies to CD31, CD34, and factor VIII-related antigen. Ultrastructurally, these malignant spindle cells contained Weibel-Palade bodies. No features suggesting radiation dermatitis (sclerosis or bizarre, large fibroblasts) were identified, but lymphangiectases and widely spaced collagen bundles(lymphedema) were prominent in the skin surrounding the angiosarcoma. Computed tomographic scan of the abdomen highlighted this histologic finding by demonstrating tumor masses limited to areas of lymphedema. Treatment with intravenous and local injections of recombinant interleukin 2 (rIL 2) followed by electron beam irradiation were initially effective with tumor remission for 2 months. However, the recurrent tumor did not respond to a second course of one-shot injection of rIL 2 through the abdominal aorta and the patient succumbed to her angiosarcoma 19 months after diagnosis.


CONCLUSIONS
Radiation-induced lymphedema may be a factor in angiosarcoma associated with radiotherapy.
Kiyohara
Takahiro
T
Department of Dermatology, Fukui Medical University, Yoshida-gun, Japan. kiyo@fmsrsa.fukui-med.ac.jp
Kumakiri
Masanobu
M
Kobayashl
Hitoshi
H
Itoh
Kei
K
Lao
Li-Min
LM
Ohkawara
Akira
A
Nakmura
Hideki
H
D000368:Aged; D003037:Cobalt Radioisotopes / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D006394:Hemangiosarcoma / Q000188:drug therapy / Q000209:etiology* / Q000532:radiotherapy / Q000648:ultrastructure; D006801:Humans; D007376:Interleukin-2 / Q000627:therapeutic use; D008209:Lymphedema / Q000209:etiology; D009381:Neoplasms, Radiation-Induced / Q000473:pathology*; D016609:Neoplasms, Second Primary / Q000209:etiology*; D009383:Neoplasms, Vascular Tissue / Q000188:drug therapy / Q000209:etiology* / Q000532:radiotherapy / Q000648:ultrastructure; D018714:Radiotherapy, Adjuvant / Q000009:adverse effects*; D002583:Uterine Cervical Neoplasms / Q000532:radiotherapy
D003037:Cobalt Radioisotopes; D007376:Interleukin-2